The antiangiogenic activities of anlotinib (which targets receptor tyrosine kinases) and bevacizumab (which inhibits VEGF-A) have led to their being drugs of choice for many cancers, including NSCLC (48, 49). This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.